Posts Tagged ‘Ozempic’

More News Points to Explosive Growth for GLP-1 Medicines

February 7, 2024 — Let’s be clear from the start. Hype about “weight loss” drugs is exquisitely unhelpful. This is because weight loss is only an acute effect of new medicines that act on GLP-1 receptors and related pathways that influence obesity. The real need for these medicines is to control a whole range of chronic health problems that […]

Block That Metaphor! Ozempic Orthodontia

January 18, 2024 — E.B. White is long gone from this life and Block That Metaphor! is dormant at The New Yorker. But we need them back. The Washington Post has a new and twisted metaphor about obesity treatment, casting Ozempic as something like orthodontia. Kate Cohen writes: “I always thought I’d be thin if I were rich. “I’d […]

2023: The Year Ozempic Took Over the World, for Better or Worse

December 26, 2023 — In the New Yorker, Dhruv Khullar calls 2023 “the year of Ozempic.” Then in Vox, Constance Grady puts it right up there with Barbie, calling this “the year of Ozempic bodies and Barbie Botox.” The New York Times puts it at the very top of five health lessons we learned in 2023. Most notably, Science […]

Angst About Holiday Food, Health, and Happiness

December 23, 2023 — The approach of the big holiday of Christmas often conjures thoughts about sharing meals and festive food. Many tables are overflowing with excess and with that excess comes a certain amount of angst about holiday food, health, and personal happiness. This year, we have a new twist on how to cope. Popular media is serving […]

What Became of Trends We Expected to Shape 2023?

December 11, 2023 — “Prediction is difficult, especially if it’s about the future.” Niels Bohr and Yogi Berra both get credit for this pithy bit of wisdom, but the truth is that the proverbial expression has a Danish origin and an unknown author. So now that wit and wisdom emboldens us to look back at the trends we thought […]

The Catch-Up Game Begins in Obesity and Diabetes Medicines

November 25, 2023 — Two weeks ago, a shift started in the public messaging about semaglutide supply issues that have dogged Novo Nordisk from the very beginning of launching a version of this drug (Wegovy) for obesity. Has the catch-up game in production capacity for obesity and diabetes medicines begun at last in earnest? At the beginning of November, […]

Food, Family, and Gratitude in Play at Thanksgiving

November 23, 2023 — If we grant that this is the year of Ozempic, then perhaps the flood of stories about how Ozempic will mix with the food-focused holiday of Thanksgiving should not surprise us. Will it throw us all off because it robs us of a “food orgy” as the AP suggests? Or will we find a better […]

The Fake Line Between Obesity and Other Metabolic Disease

November 13, 2023 — Nestled in the midst of a lot of good news last week was a nasty reminder of a persistent problem. It’s the fake line that people persist in drawing between obesity and other metabolic disease. Lilly did it (with consent from FDA) when they decided to put a different brand name on tirzepatide for obesity. […]

Tirzepatide Approved for Obesity: Will Competition Help?

November 9, 2023 — In an era of tremendous change for obesity care, this is certainly a huge milestone. FDA approved tirzepatide for obesity treatment yesterday and put Lilly in the position to offer serious competition to Novo Nordisk. But the question that matters most to us is simple. How will this competition help people seeking to cope with […]

GLP-1 Supply Issues: Both Companies on Their Toes?

November 3, 2023 — Novo Nordisk and Eli Lilly updated their investors yesterday on their performance through the third quarter of 2023 and the word is that they are “raking in cash” from their new medicines that work so well in obesity. Gobs of money seem to be flowing to both companies, but the stories they were telling about […]